{"ATC Code":"N05CD08","Abbreviation":"","Aliases":["Buccolam","Midazolamum","8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine","mezolam","Nayzilam","Midazolam civ","USL261","USL-261","8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin","8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine"],"Biological Half-Life":"**Intravenous**:  Six single-dose pharmacokinetic studies involving healthy adults yield an elimination half-life of 1.8 to 6.4 hours (mean of approximately 3 hours).  **Intramuscular** Following IM administration of 10 mg midazolam, the mean (±SD) elimination half-life of midazolam was 4.2 (±1.87) hours.  **Intranasal** Following the administration of NAYZILAM in clinical trials, median midazolam and 1-hydroxy-midazolam elimination half-lives ranged from 2.1 to 6.2 hours and 2.7 to 7.2 hours, respectively, independent of dose.   **Oral** The mean elimination half-life of midazolam ranged from 2.2 to 6.8 hours following single oral doses of 0.25, 0.5, and 1.0 mg/kg of midazolam HCl syrup.  **Buccal* The initial and terminal elimination half-lives are 27 and 204 minutes, respectively.","Boiling Point":"496.9±55.0","CAS":"59467-70-8","ChEBI":"CHEBI:6931","ChEMBL":"CHEMBL655","ChemicalClasses":["imidazobenzodiazepine"],"Chirality":"achiral","Classes":null,"Color/Form":"Colorless crystals from ether/methylene chloride/ hexane","DEA no":2884,"Decomposition":"When heated to decomposition it emits toxic fumes of /hydrogen fluoride, hydrogen chloride and nitrogen oxides/.","Drug Classes":"Breast Feeding; Lactation; Milk, Human; Anticonvulsants; Hypnotics and Sedatives; Anti-Anxiety Agents; Benzodiazepines; Anesthetics, Intravenous","Drug Indication":"Midazolam has different indications depending on its formulation by the FDA.   **Nasal**   For the nasal spray formulation, midazolam is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.   **Intravenous**   For the intravenous injection formulation, midazolam is indicated as an agent for sedation/anxiolysis/amnesia and prior to or during diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography, cardiac catheterization, oncology procedures, radiologic procedures, suture of lacerations and other procedures either alone or in combination with other CNS depressants. The sedative, anxiolytic and amnestic use of midazolam can also be employed pre-operatively. It can also be indicated for induction of general anesthesia, before administration of other anesthetic agents or as a component of intravenous supplementation of nitrous oxide and oxygen for a balanced anesthesia. A relatively narrower dose range of midazolam and a shorter period of induction can be achieved if midazolam is combined with narcotic premedication. Finally, midazolam can be indicated as a continous intravenous infusion for sedation of intubated and mechanically ventilated patients as a component of anesthesia or during treatment in a critical care setting.  **Intramuscular**   For the intramusuclar injection formulation, midazolam is indicated for preoperative sedation/anxiolysis/amnesia or for treatment of status epilepticus in adults.  **Oral**  Midazolam syrup is indicated for use in pediatric patients for sedation, anxiolysis and amnesia prior to diagnostic, therapeutic or endoscopic procedures or before induction of anesthesia. It is only approved in monitored settings only and not for chronic or home use.  In Europe, a buccal formulation of midazolam is also approved for the treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to \u003c 18 years). For infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.","Drug Warnings":"/BOXED WARNING/ WARNING: Adult and Pediatric: Intravenous midazolam has been associated with respiratory depression and respiratory arrest, especially when used for sedation in noncritical care settings. In some cases, where this was not recognized promptly and treated effectively, death or hypoxic encephalopathy has resulted. Intravenous midazolam should be used only in hospital or ambulatory care settings, including physicians' and dental offices, that provide for continuous monitoring of respiratory and cardiac function, i.e., pulse oximetry. Immediate availability of resuscitative drugs and age- and size-appropriate equipment for bag/valve/mask ventilation and intubation, and personnel trained in their use and skilled in airway management should be assured. For deeply sedated pediatric patients, a dedicated individual, other than the practitioner performing the procedure, should monitor the patient throughout the procedure. The initial intravenous dose for sedation in adult patients may be as little as 1 mg, but should not exceed 2.5 mg in a normal healthy adult. Lower doses are necessary for older (over 60 years) or debilitated patients and in patients receiving concomitant narcotics or other central nervous system (CNS) depressants. The initial dose and all subsequent doses should always be titrated slowly; administer over at least 2 minutes and allow an additional 2 or more minutes to fully evaluate the sedative effect. The use of the 1 mg/mL formulation or dilution of the 1 mg/mL or 5 mg/mL formulation is recommended to facilitate slower injection. Doses of sedative medications in pediatric patients must be calculated on a mg/kg basis, and initial doses and all subsequent doses should always be titrated slowly. The initial pediatric dose of midazolam for sedation/anxiolysis/amnesia is age, procedure, and route dependent. Neonates: Midazolam should not be administered by rapid injection in the neonatal population. Severe hypotension and seizures have been reported following rapid IV administration, particularly with concomitant use of fentanyl.","DrugClasses":["depressant"],"DurationOfAction":"1 - 6 hours","EINECS":"261-774-5","EliminationHalfLife":"1.5 – 2.5 hours","European Community (EC) Number":"261-774-5","FDA Pharmacological Classification":"R60L0SM5BC","FullSalts":["Midazolam hydrochloride","Midazolam maleate"],"HMDB ID":"HMDB0014821","HeavyAtomCount":23,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Anticonvulsants; Hypnotics and Sedatives; Anti-Anxiety Agents; Benzodiazepines; Anesthetics, Intravenous","IUPACName":"8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine","Impurities":["reduced reduced midazolam","5,6-dihydromidazolam","8-chloro-6-(o-fluorophenyl)-1-methyl-4h-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylic acid","midazolam 6h-isomer","norflurazepam","midazolam nitromethylene compound","7-chloro-5-(2-fluorophenyl)-2,3-dihydro-1h-1,4-benzodiazepine-2-methanamine","reduced midazolam","6-chloro-2-methyl-4-(2-fluorophenyl)quinazoline","midazolam 5-oxide","desfluoromidazolam"],"InChI":"InChI=1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3","InChIKey":"DDLIGBOFAVUZHB-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Ultrashort-acting anesthetics that are used for induction. Loss of consciousness is rapid and induction is pleasant, but there is no muscle relaxation and reflexes frequently are not reduced adequately. Repeated administration results in accumulation and prolongs the recovery time. Since these agents have little if any analgesic activity, they are seldom used alone except in brief minor procedures. (From AMA Drug Evaluations Annual, 1994, p174) (See all compounds classified as Anesthetics, Intravenous.)","Melting Point":"161-164","MolecularFormula":"C\u003csub\u003e18\u003c/sub\u003eH\u003csub\u003e13\u003c/sub\u003eClFN\u003csub\u003e3\u003c/sub\u003e","MolecularWeight":"325.8 g/mol","Pharmacodynamics":"**General effects**  Midazolam is a short-acting benzodiazepine central nervous system (CNS) depressant. Pharmacodynamic properties of midazolam and its metabolites, which are similar to those of other benzodiazepine drugs, include sedative, anxiolytic, amnestic, muscle relaxant, as well as hypnotic activities. Benzodiazepines enhance the inhibitory action of the amino acid neurotransmitter gamma-aminobutyric acid (GABA).  Receptors for GABA are targeted by many important drugs that affect GABA function and are commonly used in the treatment of anxiety disorder, epilepsy, insomnia, spasticity, and aggressive behavior.  **Sedation and memory**  The onset of sedation after intramuscular administration in adults is 15 minutes, with maximal sedation occurring 30-60 minutes after injection. In one study of adults, when tested the following day, 73% of the patients who were administered midazolam intramuscularly had no recollection of memory cards shown 30 minutes following drug administration; 40% had no recollection of the memory cards shown 60 minutes after drug administration. Onset time of sedative effects in pediatric patients begins within 5 minutes and peaks at 15-30 minutes depending upon the dose administered. In the pediatric population, up to 85% had no memory of pictures shown after receiving intramuscular midazolam compared to 5% of the placebo control group.  Sedation in both adult and pediatric patients is reached within 3 to 5 minutes post intravenous (IV) injection. The time of onset is affected by the dose administered and the simultaneous administration of narcotic pre-medication. Seventy-one (71%) percent of the adult patients in clinical endoscopy studies had no memory of insertion of the endoscope; 82% of the patients had no memory of withdrawal of the endoscope.  **Anesthesia induction**  When midazolam is administered intravenously (IV) for anesthetic induction, induction of anesthesia occurs in about 1.5 minutes when narcotic pre-medication has been given and in 2 to 2.5 minutes without narcotic pre-medication/ other sedative pre-medication. Impairment in a memory test was observed in 90% of the patients.","Physical Description":"Solid","PrevSalts":["hydrochloride","maleate"],"PubChemId":4192,"Record Description":["Midazolam is an imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively. It has a role as a GABAA receptor agonist, an anticonvulsant, an anxiolytic drug, an apoptosis inducer, an antineoplastic agent, a muscle relaxant, a sedative, a general anaesthetic and a central nervous system depressant. It is an organochlorine compound, an imidazobenzodiazepine and a member of monofluorobenzenes.","Midazolam is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Depressants substance.","Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called benzodiazepines. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal, intramuscular (IM), and intravenous (IV) routes and has been used in various biomedical applications, including dentistry, cardiac surgery, and endoscopic procedures as pre-anesthetic medication, and as an adjunct to local anesthesia.  This drug was initially approved by the US FDA in 1985, and has been approved for various indications since. In late 2018, the intramuscular preparation was approved by the FDA for the treatment of status epilepticus in adults. In May 2019, the nasal spray of midazolam was approved for the acute treatment of distinctive intermittent, stereotypic seizure episodes in patients 12 years of age and older. Midazolam is considered a schedule IV drug in the United States due to the low potential for abuse and low risk of dependence.","Midazolam is a Benzodiazepine.","Midazolam is an intravenously administered benzodiazepine used as an anesthetic for conscious sedation for minor procedures and as an adjunct for general anesthesia. Midazolam has not been associated with serum aminotransferase elevations during therapy and has not been linked to cases of clinically apparent liver injury.","Midazolam is a short-acting benzodiazepine derivative with an imidazole structure and with anxiolytic, amnestic, hypnotic, anticonvulsant and sedative properties. Midazolam exerts its effect by binding to the benzodiazepine receptor at the gamma-aminobutyric acid (GABA) receptor-chloride ionophore complex in the central nervous system (CNS). This leads to an increase in the opening of chloride channels, membrane hyperpolarization and increases the inhibitory effect of GABA in the CNS. Midazolam may also interfere with the reuptake of GABA, thereby causing accumulation of GABA in the synaptic cleft.","MIDAZOLAM is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved and 112 investigational indications. This drug has a black box warning from the FDA.","A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients.  It is water-soluble at pH less than 4 and lipid-soluble at physiological pH. [PubChem] Midazolam is a schedule IV drug in the United States.","A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.","See also: Midazolam Hydrochloride (has salt form); Midazolam Maleate (is active moiety of).","Midazolam is an imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively. It has a role as a GABAA receptor agonist, an anticonvulsant, an anxiolytic drug, an apoptosis inducer, an antineoplastic agent, a muscle relaxant, a sedative, a general anaesthetic and a central nervous system depressant. It is an organochlorine compound, an imidazobenzodiazepine and a member of monofluorobenzenes.","LiverTox|CNS|Sedative/Hypnotic|Benzodiazepine"],"RefCount":4,"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Midazolam","Name":"Midazolam","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q423071","Name":"Midazolam","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00683","Name":"Midazolam","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/4192","Name":"Midazolam","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL655","Name":"Midazolam","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6931","Name":"Midazolam","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=59467-70-8","Name":"Midazolam","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0014821","Name":"Midazolam","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07524","Name":"Midazolam","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/R60L0SM5BC","Name":"Midazolam","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID5023320","Name":"Midazolam","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 4192, Midazolam. Accessed July 4, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/4192\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/4192\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Midazolam. UNII: R60L0SM5BC. Global Substance Registration System. Accessed July 4, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/R60L0SM5BC\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/R60L0SM5BC\u003c/a\u003e","Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. March 31, 2023. Accessed July 4, 2025. \u003ca href=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003ehttps://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003c/a\u003e"],"SMILES":"CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F","Salts":["hydrochloride","maleate"],"SaltsAcidCount":[1,1],"SaltsAmineCount":[1,1],"SaltsUNII":["W7TTW573JJ","77520S18SE"],"Scheduling":[{"gov":"Australia","ref":[],"schedule":"S4 substance"},{"gov":"Brazil","ref":["3"],"schedule":"B1 substance"},{"gov":"Canada","ref":[],"schedule":"Schedule IV substance"},{"gov":"Germany","ref":[],"schedule":"prescription only/Anlage III substance"},{"gov":"New Zealand","ref":[],"schedule":"Class C substance"},{"gov":"United Kingdom","ref":[],"schedule":"prescription only substance"},{"act":"Controlled Substances Act (CSA)","gov":"United States","ref":[],"schedule":"Schedule I"},{"gov":"European Union","ref":[],"schedule":"prescription only substance"}],"Solubility":"54mg/L","Stability/Shelf Life":"Midazolam hydrochloride is reportedly stable at a pH of 3-3.6.","StoreUNII":["R60L0SM5BC"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="104.085mm" version="1.2" viewBox="0 0 81.138 104.085" width="81.138mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#3050F8" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="105.0" stroke="none" width="82.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="42.507" x2="55.557" y1="1.068" y2="8.939"/>
                  
            <g class="bond" id="mol1bnd2">
                        
                <line x1="66.367" x2="55.557" y1="4.374" y2="8.939"/>
                        
                <line x1="67.316" x2="58.138" y1="6.62" y2="10.496"/>
                      
                <line class="hi" stroke="#3050F8" x1="66.367" x2="60.962" y1="4.374" y2="6.656499999999999"/>
                <line class="hi" stroke="#3050F8" x1="67.316" x2="62.727000000000004" y1="6.62" y2="8.558"/>
            </g>
                  
            <line class="bond" id="mol1bnd3" x1="72.455" x2="79.574" y1="6.31" y2="14.532"/>
                  
            <g class="bond" id="mol1bnd4">
                        
                <line x1="71.695" x2="79.574" y1="27.578" y2="14.532"/>
                        
                <line x1="70.524" x2="76.571" y1="24.801" y2="14.789"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd5" x1="71.695" x2="60.166" y1="27.578" y2="24.893"/>
                  
            <line class="bond" id="mol1bnd6" x1="55.557" x2="56.531" y1="8.939" y2="20.279"/>
                  
            <line class="bond" id="mol1bnd7" x1="53.83" x2="44.975" y1="26.559" y2="33.674"/>
                  
            <g class="bond" id="mol1bnd8">
                        
                <line x1="44.975" x2="44.975" y1="48.914" y2="33.674"/>
                        
                <line x1="42.536" x2="42.536" y1="47.505" y2="35.082"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd9" x1="44.975" x2="31.767" y1="48.914" y2="56.534"/>
                  
            <g class="bond" id="mol1bnd10">
                        
                <line x1="18.559" x2="31.767" y1="48.914" y2="56.534"/>
                        
                <line x1="20.997" x2="31.767" y1="47.505" y2="53.719"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd11" x1="18.559" x2="18.559" y1="48.914" y2="33.674"/>
                  
            <g class="bond" id="mol1bnd12">
                        
                <line x1="31.767" x2="18.559" y1="26.054" y2="33.674"/>
                        
                <line x1="31.767" x2="20.997" y1="28.869" y2="35.082"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd13" x1="44.975" x2="31.767" y1="33.674" y2="26.054"/>
                  
            <line class="bond" id="mol1bnd14" x1="18.559" x2="6.875" y1="48.914" y2="55.662"/>
                  
            <line class="bond" id="mol1bnd15" x1="44.975" x2="56.862" y1="48.914" y2="58.464"/>
                  
            <g class="bond" id="mol1bnd16">
                        
                <line x1="56.862" x2="68.391" y1="58.464" y2="55.779"/>
                        
                <line x1="57.464" x2="67.838" y1="55.82" y2="53.404"/>
                      
                <line class="hi" stroke="#3050F8" x1="68.391" x2="62.62650000000001" y1="55.779" y2="57.1215"/>
                <line class="hi" stroke="#3050F8" x1="67.838" x2="62.650999999999996" y1="53.404" y2="54.612"/>
            </g>
                  
            <line class="bond" id="mol1bnd17" x1="73.482" x2="78.299" y1="51.298" y2="41.294"/>
                  
            <line class="bond" id="mol1bnd18" x1="71.695" x2="78.299" y1="27.578" y2="41.294"/>
                  
            <line class="bond" id="mol1bnd19" x1="56.862" x2="53.476" y1="58.464" y2="73.323"/>
                  
            <g class="bond" id="mol1bnd20">
                        
                <line x1="53.476" x2="38.997" y1="73.323" y2="77.817"/>
                        
                <line x1="52.85" x2="41.06" y1="76.071" y2="79.73"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd21" x1="38.997" x2="35.587" y1="77.817" y2="92.671"/>
                  
            <g class="bond" id="mol1bnd22">
                        
                <line x1="35.587" x2="46.656" y1="92.671" y2="103.03"/>
                        
                <line x1="38.277" x2="47.291" y1="91.849" y2="100.285"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd23" x1="46.656" x2="61.234" y1="103.03" y2="98.559"/>
                  
            <g class="bond" id="mol1bnd24">
                        
                <line x1="61.234" x2="64.644" y1="98.559" y2="83.706"/>
                        
                <line x1="59.172" x2="61.952" y1="96.641" y2="84.533"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd25" x1="53.476" x2="64.644" y1="73.323" y2="83.706"/>
                  
            <line class="bond" id="mol1bnd26" x1="64.644" x2="76.507" y1="83.706" y2="80.061"/>
                  
            <path class="atom" d="M71.538 5.459h-.72l-2.619 -4.066h-.03q.012 .239 .03 .596q.023 .357 .023 .732v2.738h-.565v-4.899h.714l2.608 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm3" stroke="none"/>
                  
            <path class="atom" d="M58.802 26.573h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .358 .024 .733v2.738h-.566v-4.899h.714l2.608 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm6" stroke="none"/>
                  
            <path class="atom" d="M2.906 54.72q-.786 .0 -1.239 .53q-.452 .524 -.452 1.447q-.0 .91 .417 1.446q.422 .53 1.268 .53q.321 -.0 .607 -.054q.292 -.059 .565 -.142v.535q-.273 .102 -.565 .149q-.292 .054 -.697 .054q-.744 -.0 -1.25 -.31q-.5 -.309 -.75 -.875q-.25 -.571 -.25 -1.339q.0 -.745 .268 -1.31q.274 -.566 .804 -.881q.529 -.322 1.279 -.322q.78 .0 1.352 .286l-.244 .524q-.226 -.101 -.506 -.185q-.274 -.083 -.607 -.083zM5.662 59.143h-.601v-5.215h.601v5.215z" fill="#1FF01F" id="mol1atm13" stroke="none"/>
                  
            <path class="atom" d="M73.636 57.459h-.72l-2.62 -4.066h-.029q.012 .239 .029 .596q.024 .357 .024 .732v2.738h-.565v-4.899h.714l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.023 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm15" stroke="none"/>
                  
            <path class="atom" d="M78.459 81.68h-.613v-4.9h2.732v.542h-2.119v1.738h1.994v.542h-1.994v2.078z" fill="#90E050" id="mol1atm23" stroke="none"/>
                
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="72.455" x2="76.0145" y1="6.31" y2="10.421"/>
            <line class="hi" id="mol1bnd5" stroke="#3050F8" x1="60.166" x2="65.9305" y1="24.893" y2="26.235500000000002"/>
            <line class="hi" id="mol1bnd6" stroke="#3050F8" x1="56.531" x2="56.044" y1="20.279" y2="14.609"/>
            <line class="hi" id="mol1bnd7" stroke="#3050F8" x1="53.83" x2="49.4025" y1="26.559" y2="30.116500000000002"/>
            <line class="hi" id="mol1bnd14" stroke="#1FF01F" x1="6.875" x2="12.717" y1="55.662" y2="52.288"/>
            <line class="hi" id="mol1bnd17" stroke="#3050F8" x1="73.482" x2="75.8905" y1="51.298" y2="46.296"/>
            <line class="hi" id="mol1bnd26" stroke="#90E050" x1="76.507" x2="70.5755" y1="80.061" y2="81.8835"/>
        </g>
          
    </g>
    
</svg>
","Subjective Effects":null,"Therapeutic Uses":"Adjuvants, Anesthesia; Anesthetics, Intravenous; Anti-Anxiety Agents;  GABA Modulators; Hypnotics and Sedatives","Title":"Midazolam","UNII":"R60L0SM5BC","Wikidata":"Q423071","Wikipedia":"Midazolam","XLogP":2.5}